Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
anti-ACE2 (human), mAb (blocking) (AC384) (preservative free)
390
CHF
CHF 390.00
In stock
AG-20A-0037PF-C100100 µgCHF 390.00
AG-20A-0037PF-C500500 µgCHF 1'200.00
Figure 1: Binding of ACE2 (human) to the Spike protein of SARS-CoV-2 is inhibited by the antibody anti-ACE2 (human), mAb (blocking) (AC384) (AG-20A-0037PF).
Methods: Spike (SARS-CoV-2):Fc (human) (RBD) (rec.) (AG-40B-0194) is coated on an ELISA plate at 1µg/ml. ACE2 (human), mAb (blocking) (AC384) (AG-20A-0037PF) or an unrelated mAb Control are added (starting at 40µg/ml with a two-fold serial dilution) together with 500ng/µl of ACE2 (human) (AG-40B-0192). After incubation for 1h at RT, the binding was detected using an anti-FLAG antibody (HRP).
Methods: Spike (SARS-CoV-2):Fc (human) (RBD) (rec.) (AG-40B-0194) is coated on an ELISA plate at 1µg/ml. ACE2 (human), mAb (blocking) (AC384) (AG-20A-0037PF) or an unrelated mAb Control are added (starting at 40µg/ml with a two-fold serial dilution) together with 500ng/µl of ACE2 (human) (AG-40B-0192). After incubation for 1h at RT, the binding was detected using an anti-FLAG antibody (HRP).
| Product Details | |
|---|---|
| Synonyms | SARS Receptor; Angiotensin-converting Enzyme 2; ACEH; Metalloprotease MPROT15; SARS-CoV-2 Receptor |
| Product Type | Monoclonal Antibody |
| Properties | |
| Clone | AC384 |
| Isotype | Mouse IgG1κ |
| Immunogen/Antigen | Recombinant human ACE2. |
| Label/Conjugates | Preservative Free |
| Application |
ELISA: (direct or indirect: 1:2'000-1:10'000) Functional Application: Blocks the binding of human ACE2 to the Spike protein of SARS-Cov-2. Does not affect the enzymatic activity of human ACE2. Optimal conditions should be determined individually for each application. |
| Crossreactivity | Human |
| Specificity |
Recognizes human ACE2. |
| Purity Detail | Protein G-affinity purified. |
| Concentration | 1mg/ml |
| Formulation | Liquid. In PBS. |
| Isotype Negative Control | |
| Accession Number | Q9BYF1 |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. |
| Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Angiotensin-converting enzyme2 (ACE2) is an ectoenzyme (carboxypeptidase) with an extracellular catalytic domain that predominantly localizes at the plasma membrane and is thereby able to hydrolyze circulating peptides. ACE2 has approximately 42% sequence identity with ACE and its cytoplasmic and transmembrane domains show 48% homology to the protein collectrin, that plays a critical role in the amino acid absorption of the kidney. ACE2 converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. ACE2 is involved in the regulation of systemic blood pressure and has direct effects on cardiac functions. It is expressed predominantly in endothelial cells of the lung, gut, heart and kidney. ACE2 together with the protease TMPRSS2 acts as a functional receptor for SARS coronavirus as well as for the new highly pathogenic coronavirus, 2019-nCoV/SARS-CoV-2, which is cause for pneumonia COVID-19.
Product References
- Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2): K. Liao, et al.; J. Immunol. Meth. 389, 52 (2013)
- Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications: VB. Patel, et al.; Clin. Sci. 126, 471 (2014)
- Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection In Vitro: F. Curreli, et al.; mBio 11, e02451 (2020)
- Pomegranate Peel Extract as an Inhibitor of SARS-CoV-2 Spike Binding to Human ACE2 Receptor (in vitro): A Promising Source of Novel Antiviral Drugs: A. Tito, et al.; Front. Chem. 9, 638187 (2021)
- Relevance of VEGF and CD147 in different SARS‐CoV‐2 positive digestive tracts characterized by thrombotic damage: D. Bortolotti, et al.; FASEB J. 35, e21969 (2021)
- SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation: L. Perico, et al.; Front. Immunol. 13, 827146 (2022)
- SARS-CoV-2 infects epithelial cells of the blood-cerebrospinal fluid barrier rather than endothelial cells or pericytes of the blood-brain barrier: C. Stuedle, et al.; Fluids and Barriers of the CNS 20, 76 (2023) [Immunofluorescence]
Related Products
